ADULT AMBULATORY INFUSION ORDER

InFLIXimab Infusion
(INFLECTRA, REMICADE*)

Weight: ___________ kg       Height: ___________ cm

Allergies: ____________________________________________

Diagnosis Code: _______________________________________

Treatment Start Date: ___________  Patient to follow up with provider on date: ___________

**This plan will expire after 365 days at which time a new order will need to be placed**

GUIDELINES FOR ORDERING

1. Send FACE SHEET and H&P or most recent chart note.
2. A Tuberculin test must have been placed and read as negative within the past year (PPD or QuantiFERON Gold blood test).
3. Hepatitis B (Hep B surface antigen and core antibody) screening must be completed prior to initiation of therapy and the patient should not be infected.
4. Patients should not have an active ongoing infection, signs or symptoms of malignancy, or moderate to severe heart failure at the onset of TNF-alpha inhibitor therapy. Baseline liver function tests should be normal.
5. Patient should have regular monitoring for TB, hepatitis B, infection, malignancy, and liver abnormalities throughout therapy.

OTHER:

☐ Tuberculin (TUBERSOL, APLISOL) injection, 5 units, intradermal, ONCE, Perform prior to initiation of TNF-alpha inhibitor therapy

PRE-SCREENING: (Results must be available prior to initiation of therapy):

☐ Hepatitis B Surface AG, serum, Routine, ONCE
☐ Hepatitis B Core AB Qual, serum, Routine, ONCE
 OR
☐ Hepatitis B surface antigen and core antibody test results scanned with orders

• Tuberculin Test Result. Date: ________  ☐ Positive / ☐ Negative

LABS:

☐ Antinuclear antibody screening, Routine, ONCE, prior to initiation of TNF-alpha inhibitor therapy
☐ Basic Metabolic Set, Routine, ONCE, every _______ (visit)(days)(weeks)(months) – Circle One
☐ CBC with differential, Routine, ONCE, every _______ (visit)(days)(weeks)(months) – Circle One
☐ Liver Set (AST, ALT, BILI TOTAL, BILI DIRECT, ALK PHOS, ALB, PROT TOTAL), Routine, ONCE, every _______ (visit)(days)(weeks)(months) – Circle One
☐ HCG Beta, PLASMA, routine, ONCE, every _______ (visit)(days)(weeks)(months) – Circle One
☐ Labs already drawn. Date: __________
PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)

Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)

- acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
- diphenhydramine (BENADRYL) capsule, 50 mg, oral, ONCE, every visit
- loratadine (CLARITIN) tablet, 10 mg, oral, ONCE, every visit
  (Choose as alternative to diphenhydramine if needed)
- methylprednisolone sodium succinate (SOLU-MEDROL), 40 mg, intravenous, ONCE, every visit
  (Choose if patient has required IV steroids for a reaction during a prior TNF-alpha inhibitor infusion)

MEDICATIONS:

**Biosimilar selection (must check one) – applies to all orders below**

- INFLECTRA (InFLIXimab-dyyb)**formulary agent**
- * REMICADE (inFLIXimab) Restricted to existing REMICADE patients for continuing therapy ONLY

**Initial Doses:** (Pharmacist will use most recent weight and round dose to the nearest 100 mg vial)

- 3 mg/kg in NaCl 0.9%, intravenous
- 5 mg/kg in NaCl 0.9%, intravenous
- 10 mg/kg in NaCl 0.9%, intravenous

Interval: (must check one)

- Once
- Three doses at 0, 2, and 6 weeks; dates: Week 0______, Week 2______, Week 6______

**Maintenance Doses:** (Pharmacist will use most recent weight and round dose to nearest 100 mg vial)

- 3 mg/kg in NaCl 0.9%, intravenous
- 5 mg/kg in NaCl 0.9%, intravenous
- 10 mg/kg in NaCl 0.9%, intravenous

Interval:

- Every _______ weeks for _____ doses
NURSING ORDERS:
1. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
2. Infuse over 2 hours. For previous infusion reactions, begin all subsequent infusions at 10 mL/hr for 15 minutes, then double the rate every 15 minutes up to a maximum of 125 mL/hr.
3. Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to infusion, then every 15 minutes x 30 minutes, then every 30 minutes until infusion is completed. Consider observing patient for 60 minute following infusion.

AS NEEDED MEDICATIONS:
1. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for hypersensitivity or infusion reaction, chills, or malaise.
2. diphenhydramine (BENADRYL) capsule, 25 mg, oral, EVERY 4 HOURS AS NEEDED for itching
3. sodium chloride 0.9% solution, intravenous, 500 mL, AS NEEDED x1 dose, for TNF-alpha inhibitor infusion tolerability. Give concurrently with TNF-alpha inhibitor.

HYPERSENSITIVITY MEDICATIONS:
1. If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydramine (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x2 doses for hypersensitivity reaction, Max dose 50 mg
3. epinephrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction.

By signing below, I represent the following:
I am responsible for the care of the patient (who is identified at the top of this form);
I hold an active, unrestricted license to practice medicine in: □ Oregon □ (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);
My physician license Number is # __________________________ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.
OLC Central Intake Nurse:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient’s preferred clinic location:

☐ Beaverton
   OHSU Knight Cancer Institute
   15700 SW Greystone Court
   Beaverton, OR 97006
   Phone number: 971-262-9000
   Fax number: 503-346-8058

☐ NW Portland
   Legacy Good Samaritan campus
   Medical Office Building 3, Suite 150
   1130 NW 22nd Ave.
   Portland, OR 97210
   Phone number: 971-262-9600
   Fax number: 503-346-8058

☐ Gresham
   Legacy Mount Hood campus
   Medical Office Building 3, Suite 140
   24988 SE Stark
   Gresham, OR 97030
   Phone number: 971-262-9500
   Fax number: 503-346-8058

☐ Tualatin
   Legacy Meridian Park campus
   Medical Office Building 2, Suite 140
   19260 SW 65th Ave.
   Tualatin, OR 97062
   Phone number: 971-262-9700
   Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders